Day One Biopharmaceuticals, Inc. (DAWN)
DAWN Stock Price Chart
Explore Day One Biopharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze DAWN price movements and trends.
DAWN Company Profile
Discover essential business fundamentals and corporate details for Day One Biopharmaceuticals, Inc. (DAWN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 May 2021
Employees
181.00
Website
https://dayonebio.comCEO
Jeremy Bender
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Financial Timeline
Browse a chronological timeline of Day One Biopharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.28, while revenue estimate is $38.20M.
Earnings released on 5 Aug 2025
EPS came in at -$0.29 surpassing the estimated -$0.35 by +17.14%, while revenue for the quarter reached $33.91M , missing expectations by -14.44%.
Earnings released on 6 May 2025
EPS came in at -$0.35 surpassing the estimated -$0.46 by +23.91%, while revenue for the quarter reached $30.76M , missing expectations by -15.81%.
Earnings released on 25 Feb 2025
EPS came in at -$0.69 falling short of the estimated -$0.35 by -97.14%, while revenue for the quarter reached $29.21M , missing expectations by -3.52%.
Earnings released on 30 Oct 2024
EPS came in at $0.38 surpassing the estimated -$0.41 by +192.68%, while revenue for the quarter reached $93.76M , beating expectations by +229.17%.
Earnings released on 30 Jul 2024
EPS came in at -$0.05 surpassing the estimated -$0.67 by +92.54%, while revenue for the quarter reached $8.19M , beating expectations by +698.25%.
Earnings released on 6 May 2024
EPS came in at -$0.72 falling short of the estimated -$0.67 by -7.46%.
Earnings released on 26 Feb 2024
EPS came in at -$0.64 falling short of the estimated -$0.57 by -12.28%, while revenue for the quarter reached $560.00K .
Earnings released on 6 Nov 2023
EPS came in at -$0.54 surpassing the estimated -$0.60 by +10.00%.
Earnings released on 7 Aug 2023
EPS came in at -$0.61 falling short of the estimated -$0.60 by -1.67%.
Earnings released on 1 May 2023
EPS came in at -$0.59 surpassing the estimated -$0.60 by +1.67%.
Earnings released on 6 Mar 2023
EPS came in at -$0.56 surpassing the estimated -$0.57 by +1.75%.
Earnings released on 7 Nov 2022
EPS came in at -$0.53 matching the estimated -$0.53.
Earnings released on 4 Aug 2022
EPS came in at -$0.60 falling short of the estimated -$0.49 by -22.45%.
Earnings released on 12 May 2022
EPS came in at -$0.48 falling short of the estimated -$0.39 by -23.08%.
Earnings released on 7 Mar 2022
EPS came in at -$0.36 matching the estimated -$0.36.
Earnings released on 8 Nov 2021
EPS came in at -$0.33 falling short of the estimated -$0.28 by -17.86%.
Earnings released on 10 Aug 2021
EPS came in at -$5.04 falling short of the estimated -$0.31 by -1.53K%.
Earnings released on 27 May 2021
EPS came in at -$0.56 .
Earnings released on 31 Mar 2021
EPS came in at -$0.25 .
Earnings released on 30 Sept 2020
EPS came in at -$0.05 .
DAWN Stock Performance
Access detailed DAWN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.